Drugs / Hepatitis A vaccine
Hepatitis A vaccine
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02376036 | Feb 2015 → Feb 2017 | — | MacroGenics | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02531698 | Aug 2015 → Mar 2017 | meningococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01339000 | Apr 2011 → Apr 2016 | breast cancer, colon carcinoma, urinary bladder cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00621764 | Mar 2008 → Dec 2009 | Japanese encephalitis, hepatitis A virus infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00926419 | Jun → Nov 2009 | chickenpox, hepatitis A virus infection | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03537508 | Apr 2018 → Sep 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 44 trials | ||||||
| Phase 4 | NCT06184230 | Jan 2024 → Mar 2025 | hepatitis A virus infection | Best Healthcare Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT03231605 | Jul → Aug 2017 | hepatitis A virus infection | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT03330171 | Apr 2017 → Feb 2019 | chickenpox, hepatitis A virus infection, measles | University of Witwatersrand, South Africa | Unknown | No outcome recorded |
| Phase 4 | NCT00139113 | Sep 1996 → Jun 2001 | hepatitis A virus infection | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00000943 | ? → Nov 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00001078 | ? → May 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy22 trials | ||||||
| Phase 1 | NCT02296463 Background | Nov 2014 → Sep 2015 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
| Phase 2 | NCT05084508 Background | Feb 2022 → Feb 2024 | chickenpox | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT04515147 Comparator | Sep 2020 → Feb 2022 | COVID-19, severe acute respiratory syndrome | CureVac | Completed | No outcome recorded |
| Phase 2 | NCT02038907 Background | Mar 2014 → Jun 2015 | — | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT01446978 Comparator | Sep 2011 → Aug 2016 | — | Sormland County Council, Sweden | Unknown | No outcome recorded |
| Phase 2 | NCT00880893 Comparator | Apr 2009 → Oct 2014 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2/3 | NCT00201448 Comparator | Jun 2007 → Oct 2009 | cytomegalovirus infection | Virginia Commonwealth University | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT06806137 Background | May 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06855160 Background | Apr 2025 → Sep 2026 overdue | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06740630 Background | Jan 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06693895 Background | Nov 2024 → Nov 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT05794230 Background | Mar 2023 → Nov 2025 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04704830 Background | Apr 2021 → Mar 2023 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | Met primary |
| Phase 3 | NCT03143218 Comparator | Apr 2017 → Mar 2020 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00735644 Comparator | Aug 2008 → May 2009 | Japanese encephalitis, hepatitis A virus infection | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 4 | NCT05543642 Comparator | Oct 2022 → Apr 2025 overdue | rheumatic disorder | Oregon Health and Science University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT01824537 Comparator | Jan 2014 → Nov 2022 | human papilloma virus infection | McGill University | Completed | No outcome recorded |
| Phase 4 | NCT01028326 Comparator | Jan → Sep 2010 | streptococcal pneumonia | KEMRI-Wellcome Trust Collaborative Research Program | Unknown | No outcome recorded |
| Phase 4 | NCT00877396 Comparator | Sep 2008 → May 2011 | influenza | McMaster University | Completed | Met primary |
| Phase 4 | NCT00125008 Comparator | May 2003 → Jan 2008 | paratyphoid fever, typhoid fever | International Vaccine Institute | Completed | Met primary |
| Phase 4 | NCT00125047 Comparator | Oct 2001 → Aug 2007 | paratyphoid fever, typhoid fever | International Vaccine Institute | Completed | No outcome recorded |
| — | NCT01102296 Comparator | Jun 2009 → Mar 2012 | hepatitis | National Taiwan University Hospital | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hepatitis A Vaccine | “Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June)” NCT03143218 ↗33“Licensed pediatric hepatitis A vaccine” NCT02531698 ↗ |
| Known as | Epaxal | “Hepatitis A vaccine (Epaxal or Havrix) were given at 0 and 6 months.” NCT01446978 ↗ |
| Known as | Havrix | “Hepatitis A vaccine (Epaxal or Havrix) were given at 0 and 6 months.” NCT01446978 ↗2“one dose of Havrix (hepatitis A vaccine, IM)” NCT00201448 ↗ “a hepatitis A vaccine (Havrix)” NCT05084508 ↗ |
| Known as | HAVRIX (1440 ELISA unit)per dose. | “HAVRIX (1440 ELISA unit)per dose.” NCT01102296 ↗ |
| Known as | inactivated hepatitis A vaccine | “randomly assigned to receive a single dose of either Vi vaccine or inactivated hepatitis A vaccine” PMID 19625715 ↗ Jul 2009 |
| Modality | Vaccine | “hepatitis A vaccine” NCT00000943 ↗ |
| Route | Intramuscular | “Single dose give IM” NCT00201448 ↗ |